NeuroDerm to price IPO of 4.5 million shares between $13.00 and $16.00

Jefferies and Cowen are bookrunners; Oppenheimer, Roth Capital assist

By Devika Patel

Knoxville, Tenn., Nov. 3 – NeuroDerm Ltd. will sell 4.5 million ordinary shares in its initial public offering with a 30-day greenshoe option of 675,000 additional shares, according to a Form F-1/A filed Monday with the Securities and Exchange Commission. The deal was announced Sept. 15.

The shares will be sold at a price expected to fall between $13.00 and $16.00 per share.

Jefferies and Cowen and Co. are the joint bookrunning managers. Oppenheimer & Co. and Roth Capital Partners are the co-managers.

Proceeds will be used for product development, research, working capital and general corporate purposes.

The clinical-stage pharmaceutical company is based in Rehovot, Israel. It intends to list its stock on the Nasdaq under the symbol “NDRM.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.